Trial Profile
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Mavrilimumab (Primary)
- Indications COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- 16 Apr 2020 Planned End Date changed from 1 Jul 2020 to 1 Aug 2020.
- 16 Apr 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Aug 2020.
- 16 Apr 2020 Planned initiation date changed from 1 Apr 2020 to 1 May 2020.